within Pharmacolibrary.Drugs.ATC.C;

model C07AA06_1
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.4166666666666667,
    adminDuration  = 600,
    adminMass      = 0.005,
    adminCount     = 1,
    Vd             = 0.054,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Timolol is a non-selective beta-adrenergic antagonist (beta-blocker) used primarily to treat hypertension, angina pectoris, and in ophthalmic form for increased intraocular pressure in glaucoma. It is approved for clinical use and available in systemic and ophthalmic formulations.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported following intravenous administration in healthy adult subjects.</p><h4>References</h4><ol><li>Sheridan M Hoy, Susan J Keam, Gillian M Keating,Travoprost/timolol.,Drugs & aging,2006<a href='https://pubmed.ncbi.nlm.nih.gov/16930087/'>https://pubmed.ncbi.nlm.nih.gov/16930087/</a></li><li>Anam Fayyaz, Kati-Sisko Vellonen, Veli-Pekka Ranta, Elisa Toropainen, Mika Reinisalo, Annika Valtari, Jooseppi Puranen, Giuseppe D'Amico Ricci, Emma M Heikkinen, Iain Gardner, Marika Ruponen, Arto Urtti, Masoud Jamei, Eva M Del Amo,Ocular pharmacokinetics of atenolol, timolol and betaxolol cocktail: Tissue exposures in the rabbit eye.,European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V,2021<a href='https://pubmed.ncbi.nlm.nih.gov/34139290/'>https://pubmed.ncbi.nlm.nih.gov/34139290/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C07AA06_1;
